Product Overview

The investigational products are at various stages of development as listed below.

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at sbhonsle@titanpharm.com.

Disclaimer for Chart
Although we make a good faith effort to keep this content as current as possible, we do not have a duty to update information posted on our web site, and we will not be liable for any failure to update such information.  Last update January 2009.